Govt's FDI reforms to attract capital, create jobs: India Inc

Govt's FDI reforms to attract capital, create jobs: India Inc

Government's move to relax FDI norms in sectors, including civil aviation, single-brand retail, defence and pharma, will help attract big investments and boost job creation, India Inc said on Monday.

Biocon jumps 5 percent on nod for selling product in Japan

Biocon jumps 5 percent on nod for selling product in Japan

Shares of biotechnology major Biocon today jumped by 4.75 percent after the company received approval from the Japanese health authority to sell bio-similar product 'Insulin Glargine' in the country.

Govt paying mere 'lip service' to manufacturing sector: Kiran Mazumdar-Shaw

Govt paying mere 'lip service' to manufacturing sector: Kiran Mazumdar-Shaw

Mazumdar-Shaw is one of the few vocal Indian industrialists on government policies and is the Chairman and Managing Director of India's biggest biotech company, Biocon.

Biocon stocks gain over 5%, hit 52-week high in intra-day trade

Stocks of biotechnology major Biocon on Thursday surged over 5 percent after the company launched advanced novel therapy for the treatment of Hepatitis C at low cost.

 

NeoBiocon to sell anti-diabetic drug in UAE

Vildagliptin is available as monotherapy and in combination with metformin. Both the drugs commands over 30 percent of the DPP-IV market in the UAE.

Antim Baazi: NeoBiocon Partners with Novartis

NeoBiocon Partners with Novartis which shows good momentum in Biocon intra-day trading.

Biocon Q2 net profit jumps 3-fold at Rs 306 crore

Biotechnology major Biocon Tuesday reported an over two-fold jump in its consolidated net profit at Rs 306 crore for the second quarter ended September 30, 2015.

Investors reposed faith in our future growth prospects: Syngene

Readying to list its shares after a bumper 32-times over-subscribed IPO, biotechnology major Biocon's research arm Syngene on Thursday said the investors have reposed faith in its future growth prospects.

SEBI's insider trading norms 'draconian': Biocon's Shaw

In a sharp criticism of regulator SEBI's new insider trading norms, industry leader and Biocon chief Kiran Mazumdar Shaw Friday said these rules have "draconian intent" and will kill the ESOPs.

Biocon sets price band at Rs 240-250 for research arm's IPO

Biotechnology major Biocon Ltd has set the price band at Rs 240-250 per equity share for the initial public offering of its research arm Syngene International Ltd.

Syngene gets nod to raise foreign investment to 44%

Syngene gets nod to raise foreign investment to 44%

Syngene, a subsidiary of Biocon, on Monday said it has received the Foreign Investment Promotion Board (FIPB) approval for raising foreign investment in the company to 44 percent from the earlier approved 10 percent.

Govt approves FDI worth Rs 4,000 cr in pharma sector

Govt approves FDI worth Rs 4,000 cr in pharma sector

Proposals for foreign direct investment amounting to around Rs 4,000 crore by four pharma and medical devices firms, including Torrent Pharmaceuticals and Biocon's research services arm Syngene, were on Wednesday approved by the government.

Biocon's arm Syngene gets SEBI nod for IPO

Syngene International, research arm of biotechnology major Biocon, has received capital markets regulator SEBI's approval to launch an initial public offer (IPO).

Biocon, Mylan drug discovery programme makes progress

Biocon shares were trading at Rs 425.90 apiece, up 0.16%, on the BSE.

Biocon Q4 consolidated net surges 78%

During the quarter, Biocon reported exceptional gain of Rs 105.06 crore on account of share sale in its research services subsidiary Syngene.

Biocon files IPO prospectus for R&D arm Syngene

Biotech firm Biocon Ltd has filed a prospectus for the initial public offering of its USD 600 million research and development arm, Syngene, it said on Thursday.

Biocon files prospectus for Syngene IPO to raise Rs 600 cr

Biotechnology major Biocon Wednesday filed prospectus with market regulator SEBI for the initial public offer of its research arm Syngene through which aims to raise around Rs 600 crore that will be used to fund its R&D programmes.

Biocon arm Syngene appoints Peter Bains as CEO

Biotechnology major Biocon's custom research arm Syngene has appointed Peter Bains as its Chief executive Officer (CEO).

Biocon arm to have 40-acre new plant in Mangalore SEZ

Biocon's research services arm Syngene International would set up a new plant at Mangalore SEZ to manufacture pharma ingredients and agro chemicals.

Mazumdar-Shaw honoured by Federation University Australia

Biocon Chairperson Kiran Mazumdar-Shaw has been honoured by Federation University Australia (FedUni) by dedicating a road at the University's Mt Helen Campus and naming it as 'Mazumdar Drive.'